2Biruni University Faculty of Medicine, Internal Medicine Center, Istanbul, Turkiye
3Department of Hepatology and Liver Transplantation Center, Demiroglu Bilim University, Group Florence Nightingale Hospitals, Istanbul, Turkiye
4Department of Internal Medicine, Haseki Training and Research Hospital, Istanbul, Turkiye
5Liver Transplantation Center, Demiroglu Bilim University, Group Florence Nightingale Hospitals, Istanbul, Turkiye; International Liver Center (ILC), Istanbul, Turkiye
Background and Aim: Combined hepatocellular-cholangiocarcinoma (CHC) requires attention clinically and pathologically after liver transplantation (LT) because of its unique biology, difficulties in diagnosis, and being rare. We aimed to present our single center experience for this incidental combined tumor. It is aimed to present our single-center experience for this incidental combined tumor.
Material and Methods: Seventeen patients with CHC were included in the study. There were 260 hepatocellular carcinoma (HCC) patients determined as the control group. Patients were evaluated for demographic, etiological, pathological features, and survival.
Results: Macrovascular and microvascular invasion levels were signifi-cantly higher in the CHC group (p<0.05). P53, CK19, and CK7 levels were significantly higher in the CHC group (p<0.05). Hepatocyte specific anti-gen level was significantly higher in the HCC group. The mean overall sur-vival was significantly higher in the HCC group (p<0.05).
Conclusion: Even though CHC is a rare liver tumor, it has features that need to be clarified regarding both survival and tumor biology. İnvestigating prognostic factors, especially in terms of survival and recurrence, will be very beneficial to identify candidates who will benefit from LT and be included in the indications for LT for CHC. This study evaluated the outcomes of patients showing combined HCC intrahepatic cholangiocarcinoma in explant pathology.